What is Polpharma?
Headquartered in Starogard Gdański, Poland, Polpharma operates as a premier manufacturer of pharmaceutical products, serving as a critical node in the European medical landscape. The company specializes in the development and production of high-quality medications, maintaining a rigorous focus on research, development, and large-scale manufacturing excellence. By integrating advanced chemical synthesis with sophisticated distribution networks, Polpharma has established itself as a dominant entity in the pharmaceutical industry, consistently meeting the complex demands of both domestic and international healthcare markets.
How much funding has Polpharma raised?
Polpharma has raised a total of $50.3M across 1 funding round:
Debt
$50.3M
Debt (2015): $50.3M with participation from European Investment Bank
Key Investors in Polpharma
European Investment Bank
Established in 1958 and headquartered in Luxembourg, European Investment Bank (EIB) is the European Union's nonprofit long-term lending and finance institution.
What's next for Polpharma?
Looking ahead, the infusion of capital is expected to accelerate Polpharma's strategic initiatives, particularly in the realms of facility modernization and capacity expansion. As the company navigates the evolving regulatory and competitive landscape of the pharmaceutical sector, this financing provides the necessary liquidity to pursue aggressive growth targets and potential technological upgrades. By prioritizing operational efficiency and market diversification, Polpharma is well-positioned to maintain its trajectory as a leader in pharmaceutical manufacturing, ensuring sustained value creation for stakeholders and continued reliability for patients relying on its diverse product portfolio.
See full Polpharma company page
